Quince Therapeutics (NASDAQ:QNCX) vs. Acumen Pharmaceuticals (NASDAQ:ABOS) Financial Survey

Acumen Pharmaceuticals (NASDAQ:ABOS) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Volatility and Risk

Acumen Pharmaceuticals has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Acumen Pharmaceuticals and Quince Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	0	0	3	1	3.25
Quince Therapeutics	0	0	0	0	N/A

Acumen Pharmaceuticals presently has a consensus price target of $9.00, suggesting a potential upside of 262.90%. Given Acumen Pharmaceuticals’ higher probable upside, equities analysts clearly believe Acumen Pharmaceuticals is more favorable than Quince Therapeutics.

Valuation & Earnings

This table compares Acumen Pharmaceuticals and Quince Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.06)	-2.34
Quince Therapeutics	N/A	N/A	-$31.39 million	($0.76)	-1.05

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Acumen Pharmaceuticals and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-24.63%	-21.87%
Quince Therapeutics	N/A	-46.04%	-24.34%

Summary

Acumen Pharmaceuticals beats Quince Therapeutics on 6 of the 11 factors compared between the two stocks.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.